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Infection of B cells with Epstein–Barr Virus (EBV) induces interleukin-10 (IL-10) production, which may contribute to
transformation. IL-10 can modulate the immune response at certain levels, playing a crucial role in balancing humoral and
cellular responses. Moreover, it can function as a growth and differentiation factor for B cells. However, the mechanism of
IL-10 induction is still unclear. Here we demonstrate that IL-10 was specifically induced by the EBV–latent membrane protein
1 (LMP1) in Burkitt’s lymphoma (BL) cell lines BL2 and BL41. In two T cell lines (Jurkat, MOLT3), two NHL cell lines (U266,
MHH-PREB1), or three Hodgkin’s disease (HD) cell lines (L428, L540, and KMH2), LMP1 did not induce IL-10 expression. In
contrast, LMP1 activated CD40 or CD54 (ICAM1) expression in the analyzed cell lines. LMP1 derivatives lacking the
C-terminal activation regions (CTAR), by deletion of the amino acids between 187 and 351 (DCTAR1) or 232 and 386
(DCTAR2), alone, or together induced IL-10 at very low amounts compared to wild-type LMP1. Inhibition of LMP1-mediated
NFkB activation by constitutive repressive IkB-a only marginally impaired IL-10 expression in BL2 cells, while SB2035080 at
5 mM (a specific p38/SAPK2 inhibitor) led to reduced IL-10 expression. Our findings confirm the role of LMP1 in transacti-
vation of cellular genes possibly important for tumor immunoescape but show that more than one signaling pathway is
involved in this activation and suggests the necessity of a defined conformation of CTARs to activate IL-10 involving
p38/SAPK2. © 2001 Academic Press
Key Words: Interleukin-10; EBV-LMP1; NFkB; p38/SAPK2; Burkitt’s lymphoma; Hodgkin’s disease.
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1INTRODUCTION
Epstein–Barr Virus (EBV), a g-Herpesvirus, is detect-
able in a number of malignancies including Burkitt’s
lymphoma (BL), Hodgkin’s disease (HD), and nasopha-
ryngeal carcinomas (NPC). Among the viral proteins,
which are expressed as a consequence of EBV infection,
the latent membrane protein 1 (LMP1) is of particular
interest. LMP1 is a major component in the process of B
cell immortalization and transformation (Kaye et al., 1993;
Kilger et al., 1998; Kulwichit et al., 1998; Zimber et al.,
1996). Expression of LMP1 induces phenotypic changes
of B cells and activates cellular genes like CD40 or
ICAM1/CD54, the NFkB transcription factor, c–jun N–ter-
inal-kinase (JNK), and the STAT pathway (Devergne et
l., 1996; Eliopoulos et al., 1997, 1999a; Gires et al., 1999;
aye et al., 1996; Kieser et al., 1997; Mitchell and Sudgen,
995; Mosialos et al., 1995). LMP1 mimics a constitutive
ctivated receptor with similarities to CD40 signaling
Eliopoulos et al., 1997; Gires et al., 1997; Hatzivassiliou
t al., 1998). The essential regions of LMP1 are six
1 To whom reprint requests should be addressed at Eberhard-Karls-
niversita¨t Universita¨tsklinikum, Institut fu¨r Tropenmedizin Sektion Hu-
anparasitologie, Wilhelmstrabe 27 D-72074 Tu¨bingen, Germany. Fax:
07071 29 5189. E-mail: dieter.kube@uni-tuebingen.de.
183ydrophobic transmembrane domains that enable li-
and-independent aggregation in the plasma membrane
nd the carboxyl-terminal region (CCR), altering cell
rowth and cellular gene activation. This cellular gene
ctivation is permitted through two major effector do-
ains: the C-terminal activation regions (CTAR) 1 and 2
Devergne et al., 1996; Floettmann and Rowe, 1997; Huen
t al., 1995; Izumi and Kieff, 1997; Mitchell and Sudgen,
995). CTAR1 (amino acids 185–211) mediates the initial
nduction of lymphocyte transformation and NFkB acti-
vation and interacts with tumor necrosis factor receptor-
associated factor (TRAF) molecules (Devergne et al., 1996;
Izumi and Kieff, 1997; Kaye et al., 1993, 1995, 1996; Kilger et
al., 1998; Mosialos et al., 1995). CTAR2 (amino acids 374–
386) is critical for long-term growth of lymphoblastoid cell
lines (Izumi and Kieff, 1997). This domain is located close to
the carboxyl-terminal end, interacts with the TNF receptor-
associated death domain protein (TRADD), and is essential
for NFkB and JNK activation (Devergne et al., 1998; Eliopou-
los et al., 1997; Eliopoulos and Young, 1998; Huen et al.,
995; Izumi and Kieff, 1997; Kaye et al., 1996; Kieser et al.,
1997; Mitchell and Sudgen, 1995).
Infection of B cells with EBV leads to expression of
interleukin-10 (IL-10). IL-10, also named “cytokine synthe-
sis inhibitory factor,” is an important regulator of the
functions of lymphoid and myeloid cells (Moore et al.,
0042-6822/01 $35.00
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184 VOCKERODT ET AL.1993). The ability of IL-10 to block the activation of cyto-
kine synthesis and several accessory cell functions ren-
ders this cytokine a potent suppressor of effector func-
tions of macrophages and T cells (de Waal Malefyt et al.,
991). The expression of IL-10 appears to be tightly
egulated since the levels of constitutive expression in
ormal cells are extremely low.
In contrast to normal hematopoietic cells, IL-10 is
xpressed at high levels in EBV-immortalized B cells,
BV-positive Burkitt’s lymphoma cell lines, and CD40
timulated B cells (Benjamin et al., 1992; Burdin et al.,
993; Finke et al., 1993; Klein et al., 1996). Recent reports
indicate that IL-10 may contribute to the regulation of
proliferation and differentiation of B cells, suggesting
that IL-10 may be involved in EBV-induced B-cell trans-
formation (Burdin et al., 1993; Moore et al., 1993; Rousset
et al., 1992). Furthermore, IL-10 is an autocrine growth
factor for HIV-associated lymphoma cells in vitro and is
important for lymphoma development in huSCID-mice
(Baiocchi et al., 1995; Beatty et al., 1997; Masood et al.,
1995). Increased levels of IL-10 were detected in sera of
patients with Hodgkin’s lymphomas and Non-Hodgkin’s
lymphomas (NHL) (Blay et al., 1993; Cortes et al., 1995;
Sarris et al., 1999; Stasi et al., 1994). In addition, in situ
hybridization of tissue sections from Hodgkin’s disease
(HD) lesions revealed IL-10 transcript expression in LMP1-
positive Hodgkin/Reed-Sternberg (H/RS) cells (Herbst et al.,
1996). However, the mechanism of the IL-10 induction by
LMP1 is still unclear (Kube et al., 1995, 1999a).
Recently, it was shown that stable expression of LMP1
in EBV-negative BL cell lines leads to the activation of
IL-10 in a dose-dependent manner, suggesting LMP1 as
a general activator for IL-10 (Nakagomi et al., 1994).
However, LMP1 expression was associated with growth
inhibition, and thus it is unclear whether the induction of
IL-10 is directed by LMP1 or due to stress-associated
factors in the process of clonal selection of transfectants
(Floettmann et al., 1996; Stordeur and Goldman, 1998). In
addition, it was not examined whether LMP1 is involved
in IL-10 induction in other lymphomas like Hodgkin’s
disease, where in contrast to Burkitt’s lymphoma LMP1 is
also expressed in the transformed tumor cells (Deacon
et al., 1993; Herbst et al., 1992). Recent data suggest that
the gene coding for IL-10 is regulated by NFkB. It was
shown that IL-10 can be activated by the HTLV-I tax
protein in Jurkat cell in parallel to an enhanced transac-
tivation activity of NFkB by binding to defined NFkB-
inding sites within the IL-10 promoter (Eskdale et al.,
997; Kube et al., 1995, 1999a; Mori et al., 1996). These
ata suggest NFkB activation by HTLV-I tax or other viral
oncogenes like LMP1 as a major cofactor for IL-10 acti-
vation, but direct evidence is still missing.
The present study was designed to investigate early
effects of LMP1 on cellular gene expression using tran-
sient transfected cells enriched by magnetic cell sorting.
It was investigated if LMP1 is sufficient to direct the
eexpression of IL-10 in different tumor-derived cell lines
known to express this viral gene in tumor cells and which
CTARs of LMP1 are involved in this process. It was
analyzed whether LMP1-activated NFkB is responsible
for IL-10 induction or whether other pathways are in-
volved in this process. This study demonstrates that
LMP1 expression activates CD40 and CD54 but not IL-10
expression in Hodgkin’s lymphoma cells, several non-
Hodgkin’s lymphoma cells, or T cells. In Burkitt’s lym-
phoma cells, LMP1 is sufficient to induce IL-10. The
CTAR1 or CTAR2 of LMP1 are necessary but not suffi-
cient to induce IL-10 in BL2. NFkB is not a dominant
factor for IL-10 expression, but the p38/SAPK2 inhibitor
SB2035080 reduces LMP1-associated IL-10 expression.
RESULTS
Transient expression of LMP1 in lymphoma cell lines
after magnetic enrichment of transfected cells
To compare the effects of LMP1 on the expression of
IL-10 in different cell lines, LMP1 was transfected into
two Burkitt’s lymphoma (BL) cell lines (BL2, BL41), two T
cell lines (Jurkat, MOLT3), and two NHL cell lines (U266,
MHH-PREB1) and in HD cell lines (L428). In addition,
LMP1 was stably transfected in L428, L540, and KMH2
HD cell lines (data not shown). The B cell lines are tumor
cell lines derived from (post-) germinal center B cells
(Ku¨ppers and Rajewsky, 1998; Rajewsky et al., 1997). All
cell lines are negative for IL-10 expression and for EBV.
Jurkat cells were included in these studies because in a
number of recently published experiments, LMP1 re-
vealed very high transactivation potential in activating
cellular genes like CD54 and the NFkB signaling path-
way (Huen et al., 1995; Mitchell and Sudgen, 1995). In BL
cell lines DG75 and BL41, it has been shown that IL-10 is
expressed in LMP1-positive clones in a dose-dependent
manner (Nakagomi et al., 1994). To analyze the effect of
LMP1 on IL-10 expression as soon as possible, we used
a transient transfection system. In addition, a transient
system avoids the difficulties of clonal selection and the
need to normalize LMP1 expression levels. Since the
transfection efficiency of lymphoid cells generally is low,
it is important to enrich LMP1-positive cells after trans-
fection. A cotransfection system that combines a LMP1
expressing vector together with an expression vector
coding for a truncated surface antigen not expressed on
the surface of the corresponding cell line was used. This
truncated surface antigen allows the enrichment of
transfected cells 24–48 h after transfection by surface-
antigen-specific magnetic cell separation. For enrich-
ment of B cells, a truncated CD4 molecule was used as
selection marker, and in case of CD41 T cells, a trun-
ated murine MHC molecule (H-2Kk). Usually, trans-
ected cells were enriched from 5–15% surface-antigen-
xpressing cells to 90–95% (Fig. 1A).
LMP1 protein expression in various cell lines was
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185LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMAdemonstrated by Western blot analysis. (Fig. 1B). LMP1
expression levels under control of SV40 promotor (pSG5,
24h after MACS enrichment) in transfected cells were
comparable to those expressed in an EBV-superinfected
BL cell line (BL41 B95–8) and the EBV-positive HD cell
line L591. To show that LMP1 was functional in this
transient system, CD40 and CD54 expression, which has
been shown to become activated by LMP1 in various
cells, was analyzed. After transfection and enrichment of
transfected cells, CD54 was activated by LMP1 in all cell
lines (BL2, BL41, U266, MHH-PREB1, and L428) with ex-
ception of MOLT3 cells. CD40 was activated only in the
B cell lines L428, BL2, and BL41 and in MHH-PREB1 but
not in T cells and U266 myeloma cells (Table 1). Thus,
this enrichment system is useful to analyze the influence
of LMP1 on IL-10 expression.
IL-10 is induced by LMP1 exclusively in Burkitt’s
lymphoma cells but not in non-Burkitt’s lymphoma
cells or Hodgkin’s lymphoma cells
IL-10 expression was analyzed by ELISA in superna-
tants of transfected cells after MACS enrichment (Table
1). All experiments were repeated three times. LMP1
FIG. 1. Expression of LMP1 in lymphoid cells after enrichment of t
pSG5-LMP1 and pMACS4.1 (DCD4) expression vectors before and
transfection, cells were enriched by magnetic separation. The vertica
expression. A total of 14.2% of the cells were stained with a-CD4-PE bef
B) Western blot analysis of LMP1 expression in L591, MHH-PREB1, U
f cells after transfection with the gene constructs pSG5 or pSG5-LMP
arker. At 24 h after magnetic separation, equal aliquots (2.5 3 104)
nitrocellulose filters, the blot was probed with the CS.1-4 pool of mon
13.5 3 104 cells) of cell lysates from the EBV superinfected BL41 ce
quantification of LMP1 expression in the transfected cell lines.expression resulted in IL-10 induction in both analyzed
BL cell lines. In BL2 cells, the expression of LMP1 led tothe synthesis of 261 pg/ml IL-10, whereas in BL41, only 50
pg/ml was detected when measured 48 h after magnetic
separation. The multiple myeloma cell line U266 showed
a strong CD54 activation but did not express IL-10. In the
centroblastic NHL cell line MHH-PREB1, LMP1 was able
to activate CD40 and CD54 expression but was not
sufficient to induce IL-10 synthesis. In addition in both
analyzed T cell lines (Jurkat and MOLT3), LMP1 did not
induce IL-10 expression. In L428 HD cells, where LMP1
was expressed at comparable level, no IL-10 was de-
tected at different time intervals after MACS enrichment.
Furthermore, stable LMP1-expressing L428, L540, or
KMH2 cells (three independent clones, respectively),
corresponding vector control clones were analyzed for
IL-10 expression. Amount of IL-10 expressed by the EBV-
positive HD cell line L591 was also determined. LMP1
expression level was comparable to that of transient
LMP1 expressing L428 cells (Fig. 1B). Three representa-
tive stable LMP1-expressing clones of L540, KMH2, and
L428 cells with comparable LMP1 expression levels did
not express IL-10 (data not shown). Also in the superna-
tant of the HD cell line L591, no IL-10 was detected,
suggesting that LMP1 in vitro fails to activate IL-10 ex-
ted cells. (A) Flow cytometric analysis of BL2 cells transfected with
ositive selection of DCD4 expressing cells. Twenty-four hours after
ndicates the relative cell number, the horizontal axis indicates DCD4
gnetic separation and 93% after the enrichment (Statistical marker M1).
LT3, Jurkat, BL2, BL41, and L428 cells 24 h postmagnetic separation
a expression vector for DCD4 or H-2Kk-molecule as positive selection
were lysed and separated on 10% SDS–PAGE. Following transfer to
l antibodies and visualized by ECL. Increasing amounts (1.5; 4.5, and
BL41 B95-8) served as a positive control and were used for relativeransfec
after p
l axis i
ore ma
266, MO
1 and
of cells
oclonapression in this primary EBV-positive HD cell line.
Since the EBV genes EBNA1, LMP1, and LMP2 are
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186 VOCKERODT ET AL.expressed in primary Hodgkin/Reed-Sternberg cells, it
was analyzed whether LMP2 may induce IL-10 expres-
sion in L428 cells (Niedobitek et al., 1997). Transfection
f LMP2 into L428 cells alone or together with LMP1 was
ot sufficient to induce IL-10 expression (Table 1). Re-
ently it was shown that EBNA1 did not induce IL-10
roduction in L428 cells (Kube et al., 1999b).
In summary, the capacity of LMP1 to induce IL-10
xpression is restricted to a defined type of B cell tumors
r to a certain state of B-cell development.
L-10 is induced in Hodgkin cell lines after stimulation
ith phorbol-12-myristate-13-acetate
To analyze whether the failure of LMP1 to activate
L-10 in HD cell lines is probably due to a defect within
he IL-10 gene, the cells were stimulated with phorbol-
2-myristate-13-acetate (PMA) and analyzed for IL-10 ex-
ression. As depicted in Fig. 2 IL-10 was not induced by
MA treatment in BL41 and Jurkat cells. In BL2 cells, a
TABLE 1
IL-10 Is Induced by LMP1 Only in Burkitt’s Lymphoma Cell Lines
cell line IL-10 pg/ml/48 h CD40a CD54a
BL2
pSG5 —* 34.8 124
pSG-LMP1 261 52.9 335
BL41
pSG5 — 3.1 89.9
pSG-LMP1 50 29.5 549
U266
pSG5 — 0.6 210.7
pSG-LMP1 — 0.3 610.2
MHH-PREB1
pSG5 — 8.8 46.5
pSG-LMP1 — 38.6 314.9
Jurkat
pSG5 — 0 1.3
pSG-LMP1 — 0 71.6
MOLT3
pSG5 — 0 1.3
pSG-LMP1 — 0 0.8
L428
pSG5 — 14 965
pSG-LMP1 — 24 1457.2
pSG-LMP2 — 16.9 980
pSG-LMP1 1 LMP2 — NDc ND
Note. CD40 or ICAM1/CD54 is activated by LMP1 in Hodgkin cells,
Jurkat T cells, non-Burkitt’s lymphoma cells, and Burkitt’s lymphoma cells.
a The data were acquired directly after magnetic separation and are
resented as mean channel numbers for fluorescence intensity of one
epresentative experiment out of five. The mean fluorescence was
alculated after subtraction of isotype mean fluorescence using the
ellquest software.
b —, IL-10 amounts below 3 pg/ml which is the detection limit of the
used ELISA.
c ND, not done.ery low amount of IL-10 (18 pg/ml) was detected in the
upernatant after 32 h. PMA treatment of L428 and L540
S
ied to the induction of high amounts of IL-10 (Fig. 2),
hich clearly demonstrates the potential of HD cell lines
o produce IL-10. Thus, the lack of IL-10 induction by
MP1 in these cells was not due to a defect within the
L-10 gene. Since it has been shown by in situ hybrid-
zation that IL-10 transcripts can be detected in LMP1-
ositive H/RS cells, the transcription of IL-10 after LMP1
ransfection was analyzed by semiquantitative reverse
ranscription–PCR in L428 cells and compared to IL-10
ranscription in PMA-stimulated L428 cells (Herbst et al.,
996; Klein et al., 1996; Kube et al., 1999b; Westermann et
l., 1996). One microgram of total RNA was reverse
ranscribed; the resultant cDNA was used in serial dilu-
ions (Fig. 3). IL-10 amplimers were compared to the
orresponding GAPDH PCR products that were used as
nternal controls. GAPDH amount was normalized, and
he corresponding IL-10 amplimer signals were calcu-
ated. As depicted in Fig. 3 (histogram), IL-10 transcripts
ere approximately 10-fold higher in PMA-stimulated
ells (Fig. 3, lanes 2, a-c) than in unstimulated cells (Fig.
, lanes 1, a-c) and L428 cells transfected with pSG5 (Fig.
, lanes 3, a-c) or pSG5-LMP1 24 and 48 h after trans-
ection (Fig. 3, lanes 4, a-c, and 5, a-c, respectively).
Thus, PMA treatment of L428 cells led to IL-10 induc-
ion, whereas LMP1 expression in the same cell line was
ot sufficient to stimulate IL-10 transcription as shown in
ig. 3 (lanes 4, a-c, and 5, a-c). These experiments show
hat LMP1 was insufficient to induce IL-10 in L428 cells
lso at transcriptional level. Thus, the absence of IL-10 in
ell culture supernatants of L428 cells expressing LMP1
as due to the lack of inducing IL-10 transcription.
he C-terminal activation regions 1 and 2 (CTAR1,
TAR2) of LMP1 are necessary but not sufficient to
nduce IL-10 in BL2 Burkitt’s lymphoma cell lines
Previous studies have shown that a LMP1 mutant
acking the CTAR1 because of the deletion of amino acid
87–351 has ;60–80% of NFkB and JNK activation po-
tential of full-length LMP1 in 293 cells or Jurkat T cells
(Devergne et al., 1996; Floettmann and Rowe, 1997;
Hatzivassiliou et al., 1998; Huen et al., 1995; Kaye et al.,
996; Kieser et al., 1997; Mitchell and Sudgen, 1995).
Deletion mutants of LMP1 expressing only the CTAR1 by
lacking the amino acids 232–386 are also still capable to
activate NFkB or other signaling cascades (Eliopoulos et
l., 1999b; Floettmann et al., 1998).
To test whether the CTAR1 or CTAR2 of LMP1 is
nvolved in IL-10 induction, LMP1 derivatives lacking the
mino acids 187–351 [LMP1D(187–351)] or 232–386
LMP1 D(232–386)] were analyzed in BL2 cells (Fig. 4 A).
L2 cells were transiently transfected with different
MP1 derivatives or vector control, and the IL-10 amount
as measured at different time points after transfection.
ince deletion of amino acids in the C terminus of LMP1
s associated with a reduced recognition by the CS1-4
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187LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMApool of antibodies in Western blot analyses, LMP1-pro-
teins fused at the N terminus to a FLAG epitope were
used in the transfection assay. LMP1 mutants were de-
tected by an a-FLAG antibody. A representative Western
FIG. 2. IL-10 is induced in HD cells but not in BL and Jurkat cells a
without 20 ng/ml PMA for 1 h. Cells were washed and cultured in comp
2.5–32 h after stimulation. A representative experiment of three is sho
FIG. 3. IL-10 transcription in L428 cells after stimulation with PMA or
IL-10 and GAPDH in L428 cells without and with PMA after 24 h (lane
transfection) and pSG5-LMP1 (lanes 4, a–c, and 5, a–c, 24 and 48 h afte
of cDNA were amplified with both glyceraldehyde-3-phposphate dehyd
amount of cDNA and IL-10-specific oligonucleotides (upper panel). The size m
are depicted in histogram form after normalisation of GAPDH amplimers (botlot analysis of the LMP1 derivatives performed after
ransfection and enrichment of cells is presented in Fig.
B. LMP1 protein expression levels were comparable.
owever, full-length FLAG–LMP1 was less well recog-
rbol-12-myristae-13-acetate stimulation. Cells were incubated with or
dia. Supernatants for determination of IL-10 expression were obtained
ction with pSG5-LMP1. Semiquantitative reverse transcription PCR for
, and 2, a–c) and after transfection with pSG5 (lane 3, a–c, 48 h after
ection). RNA was reverse transcribed, and defined increasing amounts
se (GAPDH) (middle panel) specific oligonucleotides to normalize thefter photransfe
s 1, a–c
r transf
rogenaarker is the 100-bp ladder. The relative IL-10 RNA expression levels
tom panel).
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188 VOCKERODT ET AL.FIG. 4. CTAR1 and CTAR2 are differently involved in the activation of IL-10, CD40, and CD54 by LMP1 in BL2 cells. (A) Schematic representation
f the LMP1 protein and the deleted LMP1 gene sequences used in this study. Solid black lines represent wild-type (wt) and dotted lines denote
eleted LMP1 sequences. CTAR1 is located at residues 194–232 and CTAR2 at residues 351–386. (B) Expression of LMP1 mutants in transient
ransfected BL2. Western blot analysis of BL2 cells 24 h postmagnetic separation of cells after transfection with the gene constructs pSG-5,
SG-FLAG–LMP1, pSG5-FLAG–LMP1 D(187–351), pSG5-FLAG–LMP1 D(232–386), pSG5-FLAG–LMP1 D(187–351) togther with pSG5-FLAG–LMP1
(232–386) and an expression vector for DCD4-molecule as positive selection marker. Twenty-four hours after magnetic separation, equal aliquots
2.5 3 104) of cells were lysed and separated on 12.5% SDS–PAGE. Following transfer to nitrocellulose filters, the blot was probed with a-FLAG
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189LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMAnized by the FLAG–M2 antibody than the LMP1 mutants.
So filters were stripped and reprobed with the CS1-4
pool of antibodies, demonstrating that full-length FLAG–
LMP1 was expressed at similar levels as the mutants. As
illustrated in Fig. 4C and Table 2, only the full-length
FLAG–LMP1 was able to induce high levels of IL-10 in
BL2 cells in contrast to FLAG–LMP1 D(187–351), which
did not induce IL-10 synthesis under these conditions
even after prolonged cell culture (Table 2). A LMP1 mu-
tant shortened at the C-terminal end containing only the
CTAR1 [FLAG–LMP1D(232–386)] was unable to induce
IL-10 in BL2 cells (Fig. 4C, gray columns, Table 2). Even
72 h after magnetic separation, only negligible amounts
of IL10 (9 pg/ml) were detected by ELISA compared to
full-length LMP1 (303 pg/ml, Table 2). LMP1 mutants
without CTAR2 but still containing the CTAR1 and the
repeat region [FLAG–LMP1D(340–386) and FLAG–
LMP1D(355–386)] were unable to induce significant
amounts of IL-10 in BL2 cells (Table 2). Next, we ad-
dressed the hypothesis whether full-length LMP1 func-
tion could be reconstituted by coexpression of CTAR1
and CTAR2. However, coexpression of FLAG–LMP1
D(187–351) and FLAG–LMP1 D(232–386) in BL2 cells led
only to the induction of very low amounts of IL-10 (12
pg/ml) compared to the full-length FLAG–LMP1. These
results demonstrate that the CTAR1 and CTAR2 are nec-
essary but not sufficient for induction of IL-10 expression.
monoclonal antibodies and visualized by ECL. Antibodies were strip
antibodies for LMP1 detection and visualized by ECL. (C) CTAR1 and C
were transfected with the gene constructs as described above. Forty-eig
content was measured by ELISA, and the expression of surface ant
TABLE 2
CTAR1 and CTAR2 Are Necessary but not Sufficient
to Induce IL-10 in BL2 cells
IL-10 pg/ml
24a 48a 72a
Control —b — —
LMP1 51 345 303
LMP1D (187–351) — — —
LMP1D (232–386) — 8 9
LMP1D (340–386) — 10 NDc
LMP1D (355–386) — 10 ND
LMP1D (187–351) 1 LMP1D (232–386) — 9 12
Note. Cell supernatants were harvested 24–72 hours after magnetic
selection and the IL-10 content was measured by ELISA. FLAG-tagged
LMP1 are used after being cloned into pSG5 vectors
a Hours after MACS.
b —, IL-10 amounts below 3 pg/ml which is the detection limit of the
used ELISA.
c ND, not done.fluorescence intensity obtained from the vector control was substracted from d
level in full-length LMP1-expressing cells was defined as 100%. The data areThe CTAR1 and CTAR2 are involved in CD54 and
CD40 activation in BL2 in contrast to IL-10 induction
Since both CTARs alone or together were unable to
direct the LMP1-associated induction of IL-10, the effects
of these LMP1 mutants on CD40 or CD54 activation in
BL2 cells were analyzed. As described above, expres-
sion of full-length FLAG–LMP1 led to IL-10 induction of
and CD40 and CD54 activation in BL2 cells (Table 1).
Transfection of FLAG–LMP1 D(187–351) into BL2 cells
was associated with a CD40 and CD54 activation of
;40% compared to full-length FLAG–LMP1 (Fig 4 C). In
contrast, no IL-10 induction was obtained with this LMP1
mutant (Fig. 4C). Expression of FLAG–LMP1 D(232–386)
caused an CD54 activation of ;60% and CD40 activation
of ;10% of wild-type LMP1 levels, but again no IL-10
induction was observed in BL2 cells. Complementation
of CTAR1 and CTAR2 was sufficient to restore ;80% of
CD54 activation, while CD40 activation was not restored
by the contransfection of the CTAR1 and CTAR2. How-
ever, it has been reported previously by others that
complementation of CTAR1 and CTAR2 is associated
with a 50% ability to activate a NFkB-dependent ex-
ressed luciferase reporter gene (Floettmann et al., 1998;
loettmann and Rowe, 1997). Thus, coexpression of
TAR1 and CTAR2 is sufficient to activate NFkB and
CD54 but is not sufficient to induce IL-10 expression.
Nuclear factor-kB is not a dominant factor for IL-10
induction but influences TNFa, CD40, CD54, and Fas
expression
Upon NFkB activation IkB-a is proteolyzed, allowing
FkB to enter the nucleus to activate target genes. A
odified IkB-a (MAD3/IkB-a S32AS36A 5 constitutive
repressive IkB-a) where the serine residues at positions
2 and 36 are replaced by alanine functions as a con-
titutive active repressor of cytosolic NFkB. This modi-
fied IkB-a was used to investigate the role of NFkB for
L-10 induction by LMP1. Since it has been reported that
D40, CD54, and Fas activation by LMP1 correlates with
FkB activation, expression of these surface antigens in
resence or absence of IkB-a S32AS36A was evaluated
(Cahir-McFarland et al., 2000; Devergne et al., 1998;
Liljeholm et al., 1998). Furthermore, for better compari-
son, effects of IkB-a S32AS36A on expression of an
dditional cytokine was evaluated. TNFa has been de-
scribed to be regulated by NFkB in different cells and
m the nitrocellulose filters and than probed with the CS1-4 pool of
re involved in the activation of CD40 and CD54 by LMP1 in BL2. Cells
rs after magnetic selection, cell supernatants were harvested, the IL-10
was evaluated by flow cytometry. The basal CD54 and CD40 meanped fro
TAR2 a
ht hou
igensata obtained from full-lenght LMP1 and set as 100% activity. The IL-10
the means ( 6 SD) of at least five independent experiments.
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190 VOCKERODT ET AL.thus may be activated by LMP1 involving the NFkB path-
way (Bondeson et al., 1999; Ito et al., 1994).
BL2 cells were transiently cotransfected with pSG5
LMP1 (2 mg), IkB-a S32AS36A or empty vector (pCDNA)
12 mg), and pMACS4.1 (7 mg). Cells were enriched by
agnetic separation 24 h after transfection, and super-
atants of the enriched cells were collected. Transfection
f the constitutive repressor IkB-a S32AS36A (pCDNA
MAD3) into BL2 showed no major effects on the capacity
of LMP1 to induce IL-10 (Fig. 5A, gray columns). More
than 80% of the IL-10 amount was measured in super-
natants of cells transfected with IkB-a S32AS36A and
MP1 compared to LMP1 alone. This marginal inhibitory
ffect on IL-10 expression is due to the effects of the
onstitutive active IkB-a on cell proliferation, which has
een also reported by other groups (Cahir-McFarland et
l., 2000; Eliopoulos et al., 1999a; Floettmann et al., 1996).
apacity of IkB-a S32AS36A on LMP1-associated NFkB
activation was also investigated using a NFkB-depen-
ent luciferase reporter gene. As illustrated in Fig. 5A,
he LMP1-mediated NFkB activation was nearly com-
letely inhibited by the constitutive repressive IkB-a
(black columns). In addition as shown in Fig. 5B coex-
pression of constitutive repressive IkB-a and LMP1 re-
sulted in inhibition of LMP1-mediated CD40, CD54 and
Fas expression with 55% inhibition.
LMP1 induced 52 pg/ml TNF-a in BL2 cells when
easured 24 h after magnetic enrichment. This LMP1-
ssociated TNF-a induction was completely inhibited
(,7 pg/ml) in the presence of constitutive repressive
IkB-a. Thus, under the same conditions, the cytokines
L-10 and TNF-a are regulated in a different manner by
MP1. Under conditions used in the transient transfec-
ion assay in combination with the enrichment of trans-
ected cells, IkB-a S32AS36A did not significantly affect
MP1 expression (data not shown). Expression of IkB-a
S32AS36A in vector control-transfected cells did not in-
fluence the basal surface expression level of CD40,
CD54, and Fas (data not shown).
Thus, in contrast to the majority of cellular genes
activated by LMP1, the IL-10 gene is regulated by a
pathway different from NFkB.
LMP1 activates phosphorylation of p38/SAPK2,
SB203580 inhibits LMP1-mediated IL-10 induction
Since activation of the NFkB pathway by LMP1 in BL
ells was not linked to IL-10 induction, it was examined
hether the p38/SAPK2 pathway may be important for
L-10 expression. To evaluate the influence of LMP1 on
he p38/SAPK2 pathway, BL2 cells were transiently trans-
ected with pSG-LMP1 or control vector. Transfected
ells were enriched 24 h after electroporation as de-
cribed above. Cells were cultured for additional 24 h,
nd cell extracts were examined by Western blot analy-
is with antibodies specific for the activated form of38/SAPK2 (double phosphorylated) and afterward with
ntibodies directed against p38/SAPK2. As depicted in
ig. 6A LMP1 expression was associated with an en-
anced p38/SAPK2 phosphorylation (about twofold).
hus, LMP1 activation of the p38 pathway is not re-
tricted to certain epithelial cells but may be also impor-
ant for signaling pathways in Burkitt’s lymphoma cells
Eliopoulos et al., 1999b).
Recently, it has been shown that LPS-induced IL-10
expression in monocytes can be inhibited by a pyridinil
imidazole compound (SB203580) that is a specific inhib-
itor of the p38/SAPK2 activity (Foey et al., 1998). Further-
more, using this inhibitor, it could be found by others that
LMP1-mediated interleukin-6 and interleukin-8 induction
is coregulated by p38/SAPK2 (Eliopoulos et al., 1999b).
To evaluate the influence of p38/SAPK2 on LMP1-asso-
ciated IL-10 expression, BL2 cells were transiently trans-
fected with pSG-LMP1 or control vector and cultured in
the presence or absence of the specific inhibitor of the
p38/SAPK2 (SB203580). Transfected cells were enriched
24 h after electroporation, and cells were cultured for
48 h in the presence or absence of 5 mM SB203580.
Supernatants were analyzed for IL-10 expression by
ELISA. In parallel, LMP1-mediated CD54 activation was
analyzed in cells incubated with or without inhibitor. It
was found that treatment of BL2 cells with SB203580 at
5 mM caused more than twofold inhibition of LMP1-
induced IL-10 expression (Fig. 6B, black columns). The
inhibitory effect of SB203580 was specific for IL-10, be-
cause LMP1-activated CD54 expression in BL2 cells was
only marginally influenced by this p38/SAPK2 inhibitor
(Fig. 6B, gray columns).
DISCUSSION
In this study we report that IL-10 induction in vitro by
LMP1 is restricted to Burkitt’s lymphoma cells. In non-
Burkitt’s lymphoma, Hodgkin cells, and T cells, LMP1
was sufficient to activate CD40 or CD54 but not IL-10
expression, indicating that LMP1 activates cellular
genes in these cells. The lack of IL-10 induction in HD
cells was not due to an IL-10 expression defect since
PMA stimulation resulted in induction of IL-10 expression
at high levels in L428 and L540 HD cells. Interestingly,
phorbol ester treatment of Jurkat or BL cells did not
induce IL-10. Thus, the signaling pathways involved in
cellular gene activation by LMP1 obviously are more
complex as known so far especially for IL-10 and differ
significantly between Burkitt’s lymphoma and tumor cells
of different origin, for example H/RS cells. It has been
shown by Herbst and coworkers using in situ hybridiza-
tion that LMP1 expression in H/RS cells correlates with
the detection of IL-10 transcripts (Herbst et al., 1996).
However, while PMA stimulation of L428 cells led to the
induction of IL-10 transcripts and protein, LMP1 expres-
sion failed to induce IL-10 mRNA in L428 cells, demon-
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191LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMAFIG. 5. Constitutive repressive IkB-a does not prevent the induction of IL-10 by LMP1 in BL2L but regulates TNF-a, CD40, CD54 (ICAM-1), and Fas
gene-activation. (A) Effect of constitutive repressive IkB-a on LMP1-mediated IL-10, TNF-a, and NFkB activation in BL2 cells. BL2 cells were
otransfected with the LMP1- and DCD4-expression vectors and pCDNA-MAD3 (constitutive repressive IkB-adNIkBa) or the corresponding
control-vector (pCDNA). Twenty-four hours after magnetic separation, supernatants were collected and IL-10 and TNF-a expression was analyzed by
LISA (gray and white columns, respectively). In parallel, the NFkB-dependent luciferase reporter (p1242, 33 NFkB sites) was cotransfected with
SG5, pSG5-LMP1, and pCDNA-MAD3 or corresponding control-vector (pCDNA) (black columns). Data were normalized to the activity of full-length-
ype LMP1 (100%). Results are the means ( 6 SD) of at least three separate experiments. (B) Effects of constitutive repressive IkB-a on
MP1-mediated CD40, CD54, and Fas upregulation in BL2 cells. Cells were stained for CD40, CD54, and Fas cell surface expression. Filled
istograms correspond to LMP1-transfected cells, open histograms represent vector control transfected cells. To quantify the influence of constitutive
epressive IkB-a on CD40, CD54, and Fas activation, a gate was set so that 5% of vector control-transfected cells scored positive for the surface
arker analyzed. The percentages on each graph corresponds to the fraction of LMP1-expressing cells scoring positive in the absence (leftistograms) or presence of constitutive repressive IkB-a (right histograms). Expression of constitutive repressive IkB-a alone had no effect on basal
D40, CD54, and Fas cell surface expression in vector control-transfected cells.
n was
6 SD
192 VOCKERODT ET AL.strating that the lack of IL-10 protein expression in L428
cells was due to the missing IL-10 mRNA. Thus, addi-
tional factors may be involved in the observed expres-
sion of IL-10 in EBV-positive primary H/RS cells (Herbst
et al., 1996). One possible explanation may be that by-
FIG. 6. LMP1 expression activates the p38/SAPK2, IL-10 induction is
analysis of p38/SAPK2 phosphorylation in BL2 cells transfected with L
and DCD4-expression vectors and enriched 24 h hour after transfection
blot using antibodies against the phosphorylated form (upper panel) o
inhibitor SB203580 on LMP1-mediated IL-10 and CD54 activation. BL2
cultured in the presence of 5 mM SB2035080 or dimethyl sulfoxide (DMS
and again incubated with 5 mM SB2035080 or DMSO. Twenty-four ho
expression was measured by ELISA (black columns) and CD54 activatio
to the activity of full-length-type LMP1 (100%). Results are the means (stander cells that surround the H/RS cells in vivo in the
tumor tissue could be involved in the regulation of IL-10.The interaction of the H/RS cells with bystander cells like
the so called “H/RS rosseting T cells,” could be neces-
sary to achieve IL-10 expression in vivo. In line with this
finding is the observation that the only existing EBV-
positive L591 does not express IL-10 although the LMP1
d by the p38-specific inhibitor SB203580 in BL2 cells. (A) Western blot
vector control. BL2 cells were cotransfected with the LMP1-, control-,
4 h later cell lysates were assayed for p38 phosphorylation by Western
osphorylated form (lower panel) of p38. (B) Effects of the p38-specific
ere cotransfected with the LMP1- and DCD4-expression vectors and
4 h. Cells were enriched by magnetic separation 24 h after transfection
er cells and supernatants were collected and LMP1-associated IL-10
evaluated by flow cytometry (gray columns). The data were normalized
) of at least three separate experiments.reduce
MP1 or
, and 2
r unph
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urs latlevel is comparable with that of the transient transfected
cell lines in our study. As reported in this and an earlier
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193LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMAstudy, the latent membrane protein 2 (LMP2) or the nu-
clear antigen 1 (EBNA1) of EBV, usually expressed in
primary H/RS cells, did not influence the IL-10 expres-
sion in L428 cells (Kube et al., 1999b).
As mentioned above, it was shown by us that in con-
trast to IL-10 induction, LMP1 activates CD40 and CD54
in L428 HD cells and BL2 Burkitt’s lymphoma cells. Com-
parable levels of CD40 and CD54 activation were mea-
sured in both cell types. Interestingly, phorbol ester treat-
ment of Jurkat and BL cells did not lead to IL-10 induction
but to an activation of CD54 and CD40 in both cell types
(data not shown). Thus, different pathways are involved
in the regulation of IL-10, CD54, and CD40 in the ana-
lyzed cell lines.
LMP1 is known to activate a number of cellular genes
in B cells, including CD40 and CD54, mainly through
NFkB and JNK/AP1 activities (Cahir-McFarland et al.,
000; Devergne et al., 1996, 1998; Eliopoulos et al., 1997;
uen et al., 1995; Kaye et al., 1996; Kieser et al., 1997;
iller et al., 1997; Mitchell and Sudgen, 1995; Mosialos
t al., 1995). More recent studies indicate that LMP1 also
ediates activation of a Ras/mitogen-activated protein
inase (MAPK)-dependent pathway as well as the Janus
inase 3 and p38/SAPK (Eliopoulos et al., 1999b; Gires et
l., 1999; Roberts and Cooper, 1998). The signaling
vents leading to IL-10 expression in BL2 upon LMP1
xpression are unclear. To determine which functional
omain of LMP1 is involved in LMP1-mediated IL-10
xpression, different mutants of this viral protein where
ransiently expressed in BL2 cells and revealed that the
TAR1 and CTAR2 are necessary but not sufficient to
ediate IL-10 expression. In contrast, the CTAR1 or
TAR2 was sufficient to mediate CD40 and CD54 acti-
ation, indicating that the signal pathway for these cel-
ular genes differs from IL-10 regulation. Thus, NFkB or
NK activation usually mediated through the CTAR1 or
TAR2 seems not to be sufficient for IL-10 induction.
hese results correspond in part to those obtained for
he cytokine IL-6 (Eliopoulos et al., 1997, 1999b). The
ain induction of IL-10 by LMP1 seems to be directed
hrough a so far unknown interaction of both CTARs
bviously independent from NFkB and AP1. Furthermore,
oexpression of CTAR1 and CTAR2 by different LMP1
olecules, which was sufficient to restore CD54 activa-
ion at ;80% of “wild-type” LMP1, was unable to induce
L-10 expression. The effect of a mutated IkB-a molecule
was used to examine whether the interruption of the
activation of the NFkB pathway by LMP1 may influence
L-10 expression in BL2 cells. Interestingly, IL-10 induc-
ion by LMP1 was only marginally affected by NFkB-
inhibition, while TNF-a was markedly inhibited in the
same assay. The inability of constitutive repressive mu-
tant of IkB-a to inhibit the IL-10 induction by LMP1
strengthens the suggestion that LMP1, and probably EBV,
regulates IL-10 independent of NFkB in BL cells. Further-
ore, as shown by us and others, constitutive repressivekB-a only partially inhibited the LMP1-mediated CD54,
CD40, and Fas activation in some cell lines, confirming
that LMP1 signaling is complex and consists of a number
of signal mediators (Cahir-McFarland et al., 2000; Dev-
ergne et al., 1998; Eliopoulos et al., 1999b; Liljeholm et
al., 1998; Roberts and Cooper, 1998). The IL-10-promoter
contains many transcription factor binding sites includ-
ing NFkB and AP1 sites. We have previously shown that
the main promoter activity for IL-10 is located within
about 318 bp downstream from the transcriptional start
site. In this area, no consensus sequences for NFkB or
P1 were so far identified (Eskdale et al., 1997; Kube et
l., 1995, 1999a). However, the AT-rich region between
56 to 266 from the transcriptional start site was found
o be important for IL-10-promoter activity in BL36 (Kube
t al., 1999a). Recently, it has been shown that such
T-rich areas are binding sites for HMG-I(Y), which then
ould recruit a number of transcription factors to form an
nhancosome (Kim and Maniatis, 1997; Maker and
athans, 1996). Our results further demonstrate that
MP1-induced IL-10 expression in BL cells could be
egulated in a similar fashion as in macrophages, where
he expression of constitutive active IkB-a did not affect
IL-10 expression but inhibited TNF-a expression (Bond-
eson et al., 1999). As shown in the present report, LMP1
expression in Jurkat cells was not associated with IL-10
induction, while NFkB was activated ;30-fold as mea-
ured by NFkB-dependent reporter gene assay (data not
shown).
The fact that CTAR1 and CTAR2 are necessary but not
sufficient for LMP1-associated IL-10 regulation suggests
the requirement of a defined conformation of both CTARs
to induce IL-10 that is not necessary for CD54 activation
(Fischer et al., 1999; Floettmann et al., 1998). In line with
these findings are the results of Floettmann and col-
leagues, who reported that the activation domains of
LMP1 had to occur in a hetero-oligomeric complex to
mediate full signaling (Floettmann et al., 1998). In their
otransfection assays of Jurkat cells with LMP1 mutants,
here either the CTAR1 or CTAR2 were inactivated by
oint mutations, NFkB and CD54 were activated to ;50%
ompared to wild-type LMP1 levels. These and our re-
ults implicate that conformational determinants indeed
re very important for the potential of LMP1 to induce
L-10 in BL2. In addition, it cannot be ruled out that
dapter/scaffold proteins are necessary to reach the
deal conformation of LMP1 or to direct the activation of
ther signaling molecules like NFkB or AP1.
Recently, it has been reported that the p38/SAPK2
pathway coregulates with NFkB the LMP1-mediated IL-6
and IL-8 expression, suggesting an important role for this
signaling pathway in regulating cellular gene expression
by this EBV gene (Eliopoulos et al., 1999b). Furthermore,
the involvement of p38/SAPK2 in IL-10 regulation has
been shown in LPS-stimulated monocytes (Bondeson et
al., 1999; Foey et al., 1998). LMP1-mediated IL-10 induc-
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194 VOCKERODT ET AL.tion was accompanied by an enhanced phosphorylation
of p38/SAPK2 in BL2 cells. IL-10 expression was sup-
pressed by a highly specific inhibitor of p38/SAPK2
SB2035080, while this inhibitor did not influence CD54
activation. These results indicate that complex signaling
events involving SB2035080-sensitive kinases as p38/
SAPK2 contribute to IL-10 expression in BL cells.
To our knowledge this report is the first complex study
about the effects of LMP1 on the capacity to induce IL-10
in lymphoma cells of different origin (Burdin et al., 1993;
Finke et al., 1993; Klein et al., 1996; Nakagomi et al.,
1994). The organization and molecular components of
LMP1-mediated cellular gene expression are different in
the used cell lines, suggesting general differences be-
tween Burkitt’s and non-Burkitt’s lymphoma cells in their
capacity to express IL-10. In this study, the cytoplasmic C
tail of LMP1 was analyzed, and it was found that a
defined conformational interaction of linear functional
epitopes like the CTAR1 and -2 are important for IL-10
induction. Obviously, LMP1 alone is not in general an
inducer of IL-10. The cellular factors that are needed to
achieve IL-10 induction in HD cells by LMP1 are still
unknown and are under further investigation.
The present findings confirm the role of LMP1 in the
transactivation of cellular genes that may be involved in
EBV-associated B cell transformation. Furthermore, the
conformation of the carboxyl-terminal region of LMP1
could be important to recruit signal transducing proteins
for IL-10 expression. Our investigations form a basis for
further experiments in dissecting the mechanisms by
which cytokines like IL-10 are influenced by LMP1 in HD
compared to BL, which are probably involved in the
pathogenesis of these lymphoma cells.
MATERIAL AND METHODS
Cell culture and stimulation of cells
L428, L540, and KMH2 are cell lines established from
patients with Hodgkin’s disease (Drexler and Minowada,
1992). BL2, BL41, and BL41-B95/8 are Burkitt’s lymphoma
cell lines, and IARC171 is an LCL (kindly provided by M.
Falk and G. Lenoir). Jurkat and MOLT3 are T cell lines,
MHH-PREB1 is a NHL cell line, and U266 is multiple
myeloma cell line. Theses line were obtained from the
Deutsche Sammlung fu¨r Mikroorganismen. The cell lines
were maintained in RPMI 1640 supplemented with 10%
fetal calf serum and glutamine, penicillin, streptomycin
(all cell culture reagents from Sigma-Aldrich) at cell den-
sities between 2 3 105 and 1 3 106 cells/ml. The inhibitor
B 203580 was obtained from Calbiochem and dissolved
n dimethyl sulfoxide. SB 203580 was added to the cul-
ure medium at a concentration of 5 mM, and cells were
incubated for 24 h with inhibitor or dimethyl sulfoxide.
Phorbol-12-myristate-13-acetate (PMA) was obtained
from Sigma-Aldrich and dissolved in ethanol. For stimu-
lation, cells were incubated with or without 20 ng/ml
dPMA for 1 h. Cells were washed and cultured in com-
plete media for the indicated time points.
Plasmid constructs
Recombinant derivatives of the expression vector
pSG5, (Stratagene) containing the open reading frames
for LMP1 and LMP2 were kindly provided by E. Kieff; the
fragments were recloned from those vectors by EcoRI
digestion to the pBK-RSV vector (Stratagene) or to the
pCDNA vector (Invitrogen). The FLAG-tagged LMP1 (full-
length LMP1) and LMP1 deletion mutant FLAG–LMP1
D(187–351) were kindly provided by E. Kieff and K. Izumi
(Devergne et al., 1996; Izumi and Kieff, 1997). To generate
FLAG-tagged LMP1 mutants, FLAG-tagged LMP1 was
recloned as BamHI fragment into pBluescript KSII (Strat-
agene). LMP1 mutants used in these experiments were
generated by PCR using the following oligonucleotide
primers: 59 TCTTTATCTTCAGAAGAGACCTTCTCT 39, 59
GAGCGTCTAGAGGATCCTTAGCCGGCTCCACTCACGAG-
CAGGTG 39, 59 GAGCGTCTAGAGGATCCTTACATCAAAG-
GCGGGCCCTGGTCACC 39, and 59 GAGCGTCTAGAG-
GATCCTTAGCCGCCATGGCCGGAATCATGACT 39. These
oligonucleotides generate a stop codon at amino acid
232, 340, and 355, respectively. Mutated LMP1 fragments
were cloned as BglII-Xba fragment into pBluescript, FLAG–
LMP1, recloned as BamHI fragment into pSG5, and ana-
lyzed by sequencing. The pMACS4.1 and pMACS-Kk were
obtained from Miltenyi (Miltenyi Biotech GmbH). The con-
stitutive active IkB-a (MAD3/IkB-aS32AS36A) cloned into
CDNA was kindly provided by M. Ko¨rner (pCDNA-MAD3).
he luciferase reporter gene under control of 33 NFkB
elements (p1242) was kindly provided by B. Sugden (Mitch-
ell and Sudgen, 1995). pEGFP coding for green fluores-
cence protein (GFP) was obtained from Clontech.
Transfection of lymphoid cells with EBV genes and
reporter gene assays
For transient LMP1 expression, assays cells were
transfected with 10 mg pMACS4.1 or pMACS-Kk (Milteniy
Biotech GmbH) and 10 mg of the corresponding expres-
sion vector pBK-RSV, pBK–RSV-LMP1, pSG5, pSG5-LMP1,
pSG5-LMP2. All cells were transfected by electropora-
tion using the Easy-jet electroporator (Eurogentec). The
following conditions were used for transfection: 1 3 107
BL2 or BL41 cells were resuspended in 0.25 ml of RPMI,
10% FCS, 25 mM HEPES (pH 7.5) at 4° for 20 min, pulsed
at 250 V, 1350 mF, and directly transferred to fresh media
[RPMI 1640, 10 mM HEPES (pH 7.5) with 10% FCS]; 1 3
107 U266 or MHH-PREB1 cells were pulsed at 250 V and
1050 mF, while MOLT3 cells were pulsed at 220 V and
1050 mF; 1 3 107 L428 and Jurkat cells were resus-
ended in 0.5 ml and pulsed at 250 V, 1650 mF and 250
, 2100 mF, respectively. The efficiency of the transfection
ketected by CD4 or H-2K staining was between 3 and
15%. After transfection, the cells were grown for 24–48 h
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195LMP1 INDUCES IL-10 IN BURKITT ’S BUT NOT IN HODGKIN9S LYMPHOMAin RPMI 1640, 10 mM HEPES (pH 7.5) with 10% FCS, the
transfected cells were enriched by a CD4- or H-2Kk-
specific MACS and cultured for 3–5 days for analysis of
surface antigen expression and IL-10 production (Kube
et al., 1999b). For analytical experiments on IL-10 expres-
sion, only cells with a purity 75% were used. For stable
LMP1 expression, L540, KMH2, and L428 cells were
transfected with pBK-RSV, pBK -RSV-LMP1 by electropo-
ration as described above [250 V, 1500 mF (L540, KMH2)
nd 250 V, 2400 mF (L428)]. The cells were grown for 3
days without selection media and 2 days with 2 mg/ml
G418 and then selected under 1.25 mg/ml within 3
weeks. Fifty micrograms of the corresponding expres-
sion vector pBK-RSV or pBK-RSV-LMP1 was used in
these experiments.
For luciferase reporter gene assays, cells were trans-
fected with 10 mg NFkB reporter gene plasmid (p1242)
nd 1 mg pSG5 or pSG5-LMP1, respectively, in the pres-
nce or absence of MAD3/IkB-a together with 1 mg of a
MV-b-galactosidase coding vector (or 1.5 mg of a GFP-
expression vector), which was used as an internal con-
trol to correct for variations in transfection efficiency.
Transfected cells were grown for 24 h in RPMI with 10%
FCS at 37°C, collected by centrifugation, and lysed using
100 ml of the reporter lysis buffer from the luciferase
system (Promega). Cell lysates were cleared by centrif-
ugation, and the protein concentration was determined
using the Bradford method (Protein determination kit
from Biorad). Aliquots of lysate were analyzed for b-ga-
lactosidase activity, measuring the chemoluminescence
of AMPGD substrate with Emerald luminescence en-
hancement (Galactolight, Tropix) in a luminometer
(Berthold). Equal amounts of cell lysate were used for
determination of luciferase activity using beetle luciferin
(luciferase assay system, Promega). The relative lumi-
nescence (rlu) was calculated as the ratio of luciferase to
b-galactosidase activity. As positive control for transfec-
tion and luciferase activity, the pGL2-control-plasmid,
containing the SV40-promoter and enhancer, respec-
tively, was used (Promega). As background control, the
plasmid pGL2-basic, lacking the SV-40 promoter and
enhancer, respectively, was used.
MACS-enrichment of transfected cells
For selection of transfected cells were cotransfected
either with pMACS4.1 or pMACS-Kk expression vector
(Milteniy Biotec GmbH), which leads to an induction of a
truncated CD4 or H-2Kk molecule (murine major histo-
compatibility complex) molecule on the surface of the
transfected cells (Kube et al., 1999b). pMACS-Kk was
used for selection of CD4-positive T cells. Twenty-four to
48 h after transfection, the cells were washed twice with
ice-cold PBS and 2 mM EDTA. The cell pellet was resus-
7pended in PBS-0.5% BSA at a cell density of 1 3 10
cells/100 ml. a-CD4 beads or a-H-2Kk beads (Milteniy
m
Tiotec GmbH) were used at a 1:5 dilution, respectively.
ncubation with beads was for 15 min at 10°C in the dark.
he labeled cells were separated through a Mini-MACS
olumn as recommended by the manufacturer (Milteniy
iotec GmbH). The purity of the enriched cells was de-
ermined by FACS using a-CD4-PE or a-H-2Kk-PE anti-
body. The separated cells were cultured for 3–5 days in
RPMI 1640 and 10 mM HEPES (pH 7.5) with 10% fetal calf
serum at a cell density of 3 3 105 cells/ml. Supernatants,
cells for Western blot analysis and flow cytometry anal-
ysis were harvested every 24 h after MACS.
Western blot analysis
For Western blot analysis, cells were harvested and
washed with ice-cold PBS supplemented with 1 mM
sodium vanadate. The cellular extracts were prepared in
lysis buffer, boiled for 10 min, and chilled on ice. Proteins
were separated on a discontinuous SDS–PAGE with a
10–12.5% acrylamide resolving gel before electroblotting
onto nitrocellulose filters (Hybond C extra, Amersham-
Pharmacia Biotech). Equal loading of the gels was veri-
fied by Ponceau S staining. Expression of the proteins
was analyzed using the following antibodies: monoclonal
mouse a-LMP1 (CS.1–4, Dako), a-FLAG M2 Aldrich),
a-phospho-specific p38/SAPK2 (Thr180/Tyr182) antibody,
nd a-p38/SAPK2 antibody (New England Biolabs). Spe-
ifically bound antibodies were detected using peroxi-
ase (HRP)-coupled secondary goat a -mouse-antibody
or goat a-rabbit-antibody (Dako), and visualized by en-
hanced chemoluminescence (Amersham-Pharmacia
Biotech). The luminescence reaction was visualized by
exposure to Kodak-BioMax (Sigma-Aldrich).
Immunfluorescence analysis
For detection of cell-surface antigen expression, 1 3
106 cells were washed twice in PBS supplemented with
0.5% bovine serum albumin (BSA). For immunofluores-
cence staining, cells were incubated with fluorescein
(FITC)- or phycoerythrin (PE)-conjugated monoclonal an-
tibodies for 10 min on ice. After washing twice with
PBS–BSA, cells were resuspended in PBS–BSA. Flow
cytometry was performed using a FACS-Calibur (Becton-
Dickinson). Data are presented as specific mean linear
fluorescence intensity after subtraction of background
staining with isotype-matched control. Dead cells were
excluded by Propidium-Iodid staining. Monoclonal anti-
bodies used and their sources were as follows: IgG1
FITC or PE, a-CD40-FITC, a-CD54–PE (ICAM-1), a-H-
2Kk-PE (Becton-Dickinson), a-CD54-FITC (Diaclone),
a-CD4-PE (Immunotech).
LISA
Transfected cells were cultured after MACS enrich-
ent for 24 h and longer in RPMI 1640 complete medium.
he presence of IL-10 or TNF-a protein in the superna-
e196 VOCKERODT ET AL.tants was measured by a ELISA (Diaclone). The detec-
tion limit of the IL-10 ELISA was 3 pg/ml and of TNF-a
was 7 pg/ml.
Isolation of RNA and reverse transcription
polymerase chain reaction
Cytokine transcription was analyzed by reverse tran-
scription polymerase chain reaction as described previ-
ously. (Klein et al., 1996; Kube et al., 1999b; Westermann
t al., 1996) Briefly, RNA was isolated from 1 3 106 cells
using the Promega RNA-isolation kit (Promega). One
microgram of total RNA was reverse transcribed using
oligo-dT primers (Amersham-Pharmacia Biotech) and
Superscript reverse transcriptase as recommended by
the manufacturer (Life technologies). The first strand
synthesis reaction was fivefold diluted. This cDNA was
used in serial dilutions. The IL-10 amplification was com-
pared to the corresponding GAPDH PCR. The amplified
cDNA was analyzed by agarose gel electrophoresis and
visualized by ethidium bromide staining. The amplifica-
tion conditions were 90°C for 30 s, 68°C for 30 s, and
72°C for 30 s using 25 cycles for GAPDH and 35 cycles
for IL-10. IL-10 vs GAPDH signals were quantified using
NIH-Image software on an Apple Macintosh.
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